Treatment for lipodystrophy
The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
1. A method for treating lipodystrophy in a subject in need thereof, the method comprising
administering an effective amount of a compound of formula (I)
to the subject thereby to treat the lipodystrophy.
2. The method of claim 1 , wherein the lipodystrophy is HIV associated lipodystrophy.
3. The method of claim 2 , wherein the HIV associated lipodystrophy causes lipohypertrophy, lipoatrophy or a metabolic abnormality.
4. The method of claim 1 further comprising administering to the subject the compound of formula (I) in combination with a second therapeutic agent.